Proprietary topical vehicle facilitating better transdermal penetration of non-steroid anti-inflammatory drugs for all topical musculoskeletal pain indications, including OA and AR
Project is focused on the development of new advanced topical and transdermal formulations of new therapeutic entities (NTEs) in the treatment of chronic and acute conditions where systemic side effects are a major concern. The companys’ patented formulation platform provides enhanced skin permeation, product light stability with minimal irritation and adverse effects.
Safe and effective therapies for acute and chronic pain nets major unmet medical needs. Company has applied its technology platform to the development of topical NSAIDs for the treatment of joint, and muscle pain as well as neuroinflammatory pain (migraine).
Current size of the US pain market is around 25 bn USD for acute and chronic pain.
Chronic pain is an unmet medical need because of the following factors:
Two-thirds of pain sufferers have “moderate” pain, which is the population most relevant for NSAIDs: